NAA20: A Potential Drug Target for Cancer and Cellular Signaling

Target Name: NAA20

NCBI ID: G51126

NAA20

NAA20: A Potential Drug Target for Cancer and Cellular Signaling

NAA20 (dJ1002M8.1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique expression pattern has led to its potential as a diagnostic tool and target for drug development.

The NAA20 gene was first identified in the database dbGaP v2.0 by the GEO consortium. It is a non-coding RNA molecule that encodes a protein known as NAA20. The protein NAA20 is a scaffold protein that is involved in the regulation of cell division and has been implicated in various diseases, including cancer.

One of the key features of the NAA20 gene is its expression pattern. NAA20 is highly expressed in most tissues of the body, but its expression is significantly higher in certain organs, such as the brain, heart, and liver. This differential expression pattern makes NAA20 an attractive target for researchers who are looking for potential drug targets or biomarkers.

In addition to its expression pattern, NAA20 has also been shown to play a role in the regulation of cell division. Studies have shown that NAA20 can interact with the protein p21, which is a known regulator of cell division. This interaction between NAA20 and p21 suggests that NAA20 may be a useful drug target for diseases that are characterized by uncontrolled cell division, such as cancer.

Another potential mechanism by which NAA20 may be involved in the development of cancer is its role in the regulation of the microtubule network. Microtubules are a network of filaments that play a critical role in the movement of cells and are involved in many cellular processes, including cell division. Studies have shown that NAA20 is involved in the regulation of microtubule dynamics and that changes in microtubule density can have a significant impact on cellular behavior. This suggests that NAA20 may be a useful target for drugs that are designed to disrupt microtubule function and promote the growth and development of cancer cells.

In addition to its potential role in the regulation of cell division, NAA20 has also been shown to play a role in the regulation of cellular signaling pathways. NAA20 has been shown to interact with the protein FAK, which is a known regulator of cell signaling pathways. This interaction between NAA20 and FAK suggests that NAA20 may be a useful target for drugs that are designed to inhibit FAK signaling and promote the growth and development of cancer cells.

Overall, the NAA20 gene is a promising target for drug development due to its unique expression pattern and its involvement in the regulation of cell division and cellular signaling pathways. Further research is needed to fully understand the potential of NAA20 as a drug target or biomarker for various diseases.

Protein Name: N-alpha-acetyltransferase 20, NatB Catalytic Subunit

Functions: Catalytic subunit of the NatB complex which catalyzes acetylation of the N-terminal methionine residues of peptides beginning with Met-Asp, Met-Glu, Met-Asn and Met-Gln (PubMed:34230638). Proteins with cell cycle functions are overrepresented in the pool of NatB substrates. Required for maintaining the structure and function of actomyosin fibers and for proper cellular migration

The "NAA20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets